Patents Represented by Attorney, Agent or Law Firm Sherry M. Knowles, Esq.
-
Patent number: 6545007Abstract: A method for inhibiting sexual transmission of HIV comprising topically applying to the skin or epithelial tissue of a human a composition comprising a non-nucleoside reverse transcriptase inhibitor (“NNRTI”) that is able to inhibit viral replication for periods exceeding 12, 24, or even 36 days, at concentrations below even 10 &mgr;M. In one embodiment the NNRTI is a dihydro-alkyloxy-benzyl-oxopyrimidine (DABO).Type: GrantFiled: November 19, 2001Date of Patent: April 8, 2003Assignees: Idenix (Cayman) Limited, Universita Degli Studi di CagliariInventors: Jean-Pierre Sommadossi, Martin L. Bryant, Marino Artico, Paolo La Colla
-
Patent number: 6527766Abstract: A phacoemulsification and aspiration device comprising: (a) a substantially hollow housing comprising a first end and a second end; (b) an electrical resistance heating element disposed at the first end of the housing and configured to thermally irradiate a space proximal to the first end and exterior to the housing; (c) a source of electricity in electrical contact with the heating element; and (d) a vacuum source disposed at and integrally connected to the second end of the housing; and a method for treating cataracts in vivo by liquefying a cataractous lens nucleus and aspirating the same from within a surrounding lens capsule comprising the steps of: (a) thermally irradiating and liquefying a lens; and (b) aspirating the lens.Type: GrantFiled: April 27, 2000Date of Patent: March 4, 2003Assignee: Georgia Tech Research CorporationInventor: Scott Bair
-
Patent number: 6528515Abstract: The present invention is directed to a method for treating hepatitis B virus infection in humans comprising administering a synergistically effective amount of agents having known anti-hepatitis B virus activity in combination or alternation. Specifically, the invention is directed to a method for treating hepatitis B virus infection comprising administering FTC in combination or alternation with penciclovir, famciclovir or Bis-POM-PMEA. Additionally, the invention is directed to a method for treating hepatitis B virus infection comprising administering L-FMAU in combination or alternation with DAPD, penciclovir or Bis-POM-PMEA. The invention is further directed to a method for treating hepatitis B virus infection comprising administering DAPD in combination or alternation with Bis-POM-PMEA.Type: GrantFiled: November 2, 1999Date of Patent: March 4, 2003Assignee: Triangle Pharmaceuticals, Inc.Inventors: Phillip A. Furman, George R. Painter, III, David W. Barry, Franck Rousseau
-
Patent number: 6518425Abstract: Processes for the preparation of 1,3-oxathiolane nucleosides are provided that include efficient methods for the preparation of the 1,3-oxathiolane ring and subsequent condensation of the 1,3-oxathiolane with a pyrimidine or purine base. Using the processes described herein, the compounds can be provided as isolated enantiomers.Type: GrantFiled: May 15, 2000Date of Patent: February 11, 2003Assignees: Emory University, Triangle Pharmaceuticals, Inc.Inventors: George R. Painter, Dennis C. Liotta, Merrick R. Almond, Darryl G. Cleary, Josè D. Soria, Marcos Sznaidman
-
Patent number: 6512107Abstract: The present invention relates to a novel and improved process for preparing 2′-fluoro-5-methyl-&bgr;-L-arabinofuranosyluridine represented by formula (I) which shows anti-viral activity, especially potent anti-viral activity against hepatitis B-virus and Epstein-Barr virus:Type: GrantFiled: July 23, 1998Date of Patent: January 28, 2003Assignee: The University of Georgia Research FoundationInventors: Chung K. Chu, Jinfa Du, Yongseok Choi
-
Patent number: 6458773Abstract: Compounds and pharmaceutical compositions active against hepatitis B virus are provided, as is a method for the treatment of hepatitis B virus infection in humans and other host animals is provided comprising administering an effective amount of a &bgr;-L-(2′or 3′-azido)-2′,3′-dideoxy-5-fluorocytosine of the formula wherein R is H, acyl, monophosphate, diphosphate, or triphosphate, or a stabilized phosphate derivative (to form a stabilized nucleotide prodrug), and R′is H, acyl, or alkyl.Type: GrantFiled: November 5, 1999Date of Patent: October 1, 2002Assignees: Emory University, Centre National de la Recherche Scientifique, UAB Research FoundationInventors: Gilles Gosselin, Jean-Louis Imbach, Jean-Pierre Sommadossi, Raymond F. Schinazi
-
Patent number: 6444652Abstract: This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted.Type: GrantFiled: December 10, 1999Date of Patent: September 3, 2002Assignees: Novirio Pharmaceuticals Limited, Centre National da la Recherche ScientifiqueInventors: Gilles Gosselin, Jean-Louis Imbach, Martin L. Bryant
-
Patent number: 6410546Abstract: Use of MKC-442 in combination with other antiviral agents for the treatment of patients infected with HIV is disclosed.Type: GrantFiled: April 7, 1998Date of Patent: June 25, 2002Assignee: Triangle Pharmaceuticals, Inc.Inventors: Phillip A. Furman, Cary P. Moxham, David W. Barry, Katyna Borroto-Esoda
-
Patent number: 6407077Abstract: Compounds and pharmaceutical compositions active against HIV are provided, as is a method for the treatment of HIV infection in humans and other host animals is provided comprising administering an effective amount of a &bgr;-L-(2′ or 3′-azido)-2′,3′-dideoxy-5-fluorocytosine of the formula wherein R is H, acyl, monophosphate, diphosphate, or triphosphate, or a stabilized phosphate derivative (to form a stabilized nucleotide prodrug), and R′ is H, acyl, or alkyl.Type: GrantFiled: November 5, 1999Date of Patent: June 18, 2002Assignees: Emory University, Centre National de la Recherche Scientifique, The UAB Research FoundationInventors: Gilles Gosselin, Jean-Louis Imbach, Jean-Pierre Sommadossi, Raymond F. Schinazi
-
Patent number: 6395716Abstract: This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted.Type: GrantFiled: August 10, 1999Date of Patent: May 28, 2002Assignees: Novirio Pharmaceuticals Limited, Centre National da la Recherche ScientifiqueInventors: Gilles Gosselin, Jean-Louis Imbach, Martin L. Bryant
-
Patent number: 6391859Abstract: A method and composition for the treatment of HIV and HBV infections in humans and other host animals is disclosed that includes the administration of an effective amount of a [5-carboxamido or 5-fluoro]-2′,3′-dideoxy-2′,3′-didehydro-pyrimidine nucleoside or a [5-carboxamido or 5-fluoro]-3′-modified-pyrimidine nucleoside, or a mixture or a pharmaceutically acceptable derivative thereof, including a 5′ or N4 alkylated or acylated derivative, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.Type: GrantFiled: October 2, 2000Date of Patent: May 21, 2002Assignee: Emory UniversityInventors: Raymond F. Schinazi, Dennis C. Liotta
-
Patent number: 6348587Abstract: A class of 2′-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer.Type: GrantFiled: February 25, 1999Date of Patent: February 19, 2002Assignees: Emory University, University of Georgia Research Foundation, Inc.Inventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
-
Patent number: 6346627Abstract: Intermediates in the synthesis of 1,3-Oxathiolane Nucleosides.Type: GrantFiled: June 7, 1995Date of Patent: February 12, 2002Assignee: Emory UniversityInventors: Dennis C. Liotta, Raymond F. Schinazi, Woo-Baeg Choi
-
Patent number: 6245749Abstract: A method for the treatment of a host, and in particular, a human, infected with hepatitis B virus (HBV) is provided that includes administering an effective amount of a nucleotide prodrug of &bgr;- L-2′, 3′-dideoxyadenosine, wherein the prodrug component of the nucleotide provides controlled delivery of the active species.Type: GrantFiled: July 9, 1998Date of Patent: June 12, 2001Assignee: Emory UniversityInventors: Raymond F. Schinazi, Jean-Pierre Sommadossi, Gilles Gosselin, Jean-Louis Imbach
-
Patent number: 6242200Abstract: The invention provides methods for identifying compounds and compositions useful in the regulation of weight, the treatment of obesity, diabetes and other insulin resistance-related disorders hypertension, cardiovascular disease and the like. The methods comprise the use of adipocytes and predipocytes in assays and screens for compounds or compositions of interest. The present invention recognizes the presence of the sulfonylurea receptor in adipocytes and its utility in identifying compounds and in treating obesity and other insulin resistance-related disorders. In addition to assaying for agonists and antagonists of the sulfonylurea receptor, the methods of the invention also provide for identifying novel calcium channels or other calcium regulatory channels that are selectively expressed in human adipocytes as compared to human preadipocytes and for screening adipocytes for compounds that selectively antagonize calcium.Type: GrantFiled: June 12, 2000Date of Patent: June 5, 2001Assignees: Zen Bio, Inc., The University of Tennessee Research CorporationInventors: William O. Wilkison, Michael B. Zemel, Naima Moustaid-Mousse
-
Treatment of HIV by administration of &bgr;-D-2?, 3?-didehydro-2?,3?-dideoxy-5-fluorocytidine (D4FC)
Patent number: 6232300Abstract: A method and composition for the treatment of HIV and HBV infections in humans and other host animals is disclosed that includes the administration of an effective amount of a [5-carboxamido or 5-fluoro]-2′,3′-dideoxy-2′,3′-didehydro-pyrimidine nucleoside or a [5-carboxamido or 5-fluoro]-3′-modified-pyrimidine nucleoside, or a mixture or a pharmaceutically acceptable derivative thereof, including a 5′ or N4 alkylated or acylated derivative, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.Type: GrantFiled: May 12, 1999Date of Patent: May 15, 2001Assignee: Emory UniversityInventors: Raymond F. Schinazi, Dennis C. Liotta -
Patent number: 6197777Abstract: A method and composition for the treatment of HIV infection, HBV infection, or abnormal cellular proliferation in humans and other host animals is disclosed that includes the administration of an effective amount of a 1,3-oxaselenolane nucleoside or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.Type: GrantFiled: March 3, 2000Date of Patent: March 6, 2001Assignees: Emory University, The University of Georgia Research Foundation, Inc.Inventors: Raymond F. Schinazi, Chung K. Chu, Jinfa Du
-
Patent number: 6180766Abstract: Carboranyl-containing nucleosides and oligonucleotides are provided for use in boron neutron capture therapy (BNCT) and for other therapeutic and diagnostic purposes.Type: GrantFiled: December 2, 1993Date of Patent: January 30, 2001Inventors: Raymond F. Schinazi, Geraldin{acute over (e)} Fulcrand-El Kattan, Zbigniew Jan Lesnikowski
-
Patent number: 6114343Abstract: A method and composition for the treatment of HIV and HBV infections in humans is disclosed that includes administering an effective amount of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, a pharmaceutically acceptable derivative thereof, including a 5' or N.sup.4 alkylated or acylated derivative, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier. A process for the resolution of a racemic mixture of nucleoside enantiomers is also disclosed that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers.Type: GrantFiled: June 7, 1995Date of Patent: September 5, 2000Assignee: Emory UniversityInventors: Dennis C. Liotta, Raymond F. Schinazi, Woo-Baeg Choi
-
Patent number: 6069252Abstract: A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (-)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner.Type: GrantFiled: June 7, 1995Date of Patent: May 30, 2000Assignee: Emory UniversityInventors: Dennis C. Liotta, Raymond F. Schinazi, Woo-Baeg Choi